search
Back to results

Effect of Balloon Cryoablation on Left Atrial Function (CRYO-LA)

Primary Purpose

Atrial Fibrillation

Status
Completed
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Pulmonary vein isolation with cryoballoon catheter
Sponsored by
Vivek Reddy
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Atrial Fibrillation focused on measuring cryoablation, recurring arrhythmia, stroke, RF ablation, LA ablation, nodal ablation, catheter ablation

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Documented paroxysmal atrial fibrillation
  • ≥ 18 and ≤ 85 years of age
  • Failure of one or more AF Drugs (AFDs).
  • Referral for a pulmonary vein isolation catheter ablation procedure to treat atrial fibrillation
  • Ability to understand the requirements of the study
  • Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements

Exclusion Criteria:

  • Any reversible cause of AF (post-surgery, thyroid disorder, etc.)
  • More than 4 cardioversions in the prior year.
  • Patients with recent myocardial infarction (less than 2 months) or unstable angina.
  • Patients with congestive heart failure (NYHA class III or IV).
  • Patients who have experienced any cerebral ischemic event, including any TIA in the preceding 1 month.
  • Women who are known to be pregnant or have had a positive β-HCG test 7 days prior to procedure.
  • Patients with any other significant uncontrolled or unstable medical condition (including uncontrolled clinically significant coagulation disorders).
  • Patients whose life expectancy is less than one year.

Sites / Locations

    Arms of the Study

    Arm 1

    Arm Type

    Experimental

    Arm Label

    Experimental

    Arm Description

    All study subjects will undergo cryoablation. This is a non-randomized trial.

    Outcomes

    Primary Outcome Measures

    Number of Participants With Acute Procedural Success (APS)
    Acute Procedural Success (APS) is the demonstration of electrical isolation of all 4 PVs or their anomalous equivalents at the conclusion of the first protocol-defined cryoablation procedure.
    Number of Participants With AF Recurrence
    Number of Participants with AF Recurrence at 6 months and at 12 months after Cryoballoon Ablation for Atrial Fibrillation. (Chronic Treatment Success is defined as a subject who does not have episodes of AF, lasting at least 30 seconds in duration, 3 months following the initial ablation procedure.)
    Left Atrial Measurements
    Transthoracic Echo Assessment of Left Atrial Function at Baseline and 6-Months Post- Cryoballoon Ablation for AF Parameters of atrial function: Volumes at P-wave onset and end-systole LA active emptying volume LA active emptying fraction Late diastolic peak velocity LA filling fraction Pulmonary venous inflow pattern
    LVEF
    Ventricular Function measured by Left Ventricular Ejection Function (LVEF). A normal left ventricular ejection fraction (LVEF) ranges from 55% to 70%. An LVEF of 65%, for example means that 65% of total amount of blood in the left ventricle is pumped out with each heartbeat.
    Left Atrial Volume
    Transthoracic Echo Assessment of Left Atrial Function at Baseline and 6-Months Post- Cryoballoon Ablation for AF
    Deflections of the Mitral Annulus Measurement
    Transthoracic Echo Assessment of Left Atrial Function at Baseline and 6-Months Post- Cryoballoon Ablation for AF Deflections of the mitral annulus as measured by peak early ventricular diastolic velocity (E'), and during atrial contraction (A')

    Secondary Outcome Measures

    Chronic Treatment Success for the Follow-up Visit Within Treatment Windows.
    Chronic Treatment Success for the follow-up visit within treatment windows. 1. Whether on or off Atrial Fibrillation Drugs (AFDs) during the Non-blanked Follow-up Period 2. When off Atrial Fibrillation Drugs
    Atrial Flutter
    1. Flutter Acute Procedural Success 2. Freedom from Flutter Chronic Treatment Failure

    Full Information

    First Posted
    January 9, 2009
    Last Updated
    June 27, 2019
    Sponsor
    Vivek Reddy
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT00821015
    Brief Title
    Effect of Balloon Cryoablation on Left Atrial Function
    Acronym
    CRYO-LA
    Official Title
    Effect of Balloon Cryoablation on Left Atrial Function (CRYO-LA)
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    June 2019
    Overall Recruitment Status
    Completed
    Study Start Date
    June 2010 (undefined)
    Primary Completion Date
    December 2011 (Actual)
    Study Completion Date
    June 2012 (Actual)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Sponsor-Investigator
    Name of the Sponsor
    Vivek Reddy

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    Atrial fibrillation is a common and disabling irregular heart rhythm, that affects 1 to 1.5 million Americans. Recent clinical experience with the Medtronic Arctic Front™ Cardiac CryoAblation Catheter System suggests that it can be used to isolate the pulmonary veins (PVs) safely and effectively in patients with AF, thereby reducing or eliminating the recurrence of AF.3-4 However, the very large ablative surface of this balloon ablation catheter raises the possibility that this technique may damage extensive areas of the atrial myocardium. The LA is an elastic chamber, designed to expand and contract with ease to accommodate the influx and outflow of blood, while maintaining relatively low pressure. When exposed to stress or injury, whether acute or chronic, the LA may lose much of its elasticity, resulting in overall dilation accompanied by fibrosis in some cases. Overall, this may potentially result in diminution of LA mechanical function (both systolic contractile function, and diastolic relaxation function). In addition, LA function is linked to both Left Ventricular (LV) systolic and diastolic function, manifesting in an overall impact on cardiac remodeling, including the area of the pulmonary vein ostia, and a significant decrease in LV ejection fraction (LVEF). On the other hand, the positive effects of maintaining sinus rhythm with successful catheter ablation of AF may result in improvement of LA mechanical function.5-9 Based on the potentially deleterious effects of damage caused by cryoablation, to the atrial myocardium during balloon ablation, this prospective, non-randomized, single-center study has been designed to assess the atrial effects of balloon cryo-ablation.
    Detailed Description
    This study is a prospective, non-randomized, single-center, controlled study of patients with AF referred for ablation after failing one or more Class I-IV antiarrhythmic drugs used in the treatment of AF. • All study subjects will undergo cryoablation. Subjects will be followed for 12 months to assess the chronic impact of ablation with the Medtronic CryoCath Arctic Front™ Cardiac CryoAblation Catheter System on LA and LV mechanical function. In addition, patients will undergo scheduled and symptom-driven assessments to detect recurrent AF and adverse events (AEs). We will evaluate the effect of ablation with the Medtronic Arctic Front™ Cardiac CryoAblation Catheter System on the atrial myocardium, with respect to LA (and LV) mechanical function, by assessing images acquired using TTE and CT in adult patients with atrial fibrillation who have failed at least one anti-arrhythmic drug. The efficacy of the Arctic Front™ Cardiac CryoAblation Catheter System will be assessed by ambulatory continuous ECG monitoring

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Atrial Fibrillation
    Keywords
    cryoablation, recurring arrhythmia, stroke, RF ablation, LA ablation, nodal ablation, catheter ablation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Single Group Assignment
    Masking
    None (Open Label)
    Allocation
    N/A
    Enrollment
    27 (Actual)

    8. Arms, Groups, and Interventions

    Arm Title
    Experimental
    Arm Type
    Experimental
    Arm Description
    All study subjects will undergo cryoablation. This is a non-randomized trial.
    Intervention Type
    Device
    Intervention Name(s)
    Pulmonary vein isolation with cryoballoon catheter
    Intervention Description
    For each patient, the balloon catheter will be advanced to the ostium of each pulmonary vein. Once location has been optimized, the balloon will be inflated, and cryoenergy delivery will be initiated. Because the entire surface of the balloon acts as an ablative surface, circumferential ablation of each pulmonary vein will be achieved concurrently. This will be completed for each pulmonary vein for each patient.
    Primary Outcome Measure Information:
    Title
    Number of Participants With Acute Procedural Success (APS)
    Description
    Acute Procedural Success (APS) is the demonstration of electrical isolation of all 4 PVs or their anomalous equivalents at the conclusion of the first protocol-defined cryoablation procedure.
    Time Frame
    Immediately following procedure
    Title
    Number of Participants With AF Recurrence
    Description
    Number of Participants with AF Recurrence at 6 months and at 12 months after Cryoballoon Ablation for Atrial Fibrillation. (Chronic Treatment Success is defined as a subject who does not have episodes of AF, lasting at least 30 seconds in duration, 3 months following the initial ablation procedure.)
    Time Frame
    6 months and 12 months
    Title
    Left Atrial Measurements
    Description
    Transthoracic Echo Assessment of Left Atrial Function at Baseline and 6-Months Post- Cryoballoon Ablation for AF Parameters of atrial function: Volumes at P-wave onset and end-systole LA active emptying volume LA active emptying fraction Late diastolic peak velocity LA filling fraction Pulmonary venous inflow pattern
    Time Frame
    Baseline and 6 months
    Title
    LVEF
    Description
    Ventricular Function measured by Left Ventricular Ejection Function (LVEF). A normal left ventricular ejection fraction (LVEF) ranges from 55% to 70%. An LVEF of 65%, for example means that 65% of total amount of blood in the left ventricle is pumped out with each heartbeat.
    Time Frame
    Baseline and 6 months
    Title
    Left Atrial Volume
    Description
    Transthoracic Echo Assessment of Left Atrial Function at Baseline and 6-Months Post- Cryoballoon Ablation for AF
    Time Frame
    Baseline and 6 months
    Title
    Deflections of the Mitral Annulus Measurement
    Description
    Transthoracic Echo Assessment of Left Atrial Function at Baseline and 6-Months Post- Cryoballoon Ablation for AF Deflections of the mitral annulus as measured by peak early ventricular diastolic velocity (E'), and during atrial contraction (A')
    Time Frame
    Baseline and 6 months
    Secondary Outcome Measure Information:
    Title
    Chronic Treatment Success for the Follow-up Visit Within Treatment Windows.
    Description
    Chronic Treatment Success for the follow-up visit within treatment windows. 1. Whether on or off Atrial Fibrillation Drugs (AFDs) during the Non-blanked Follow-up Period 2. When off Atrial Fibrillation Drugs
    Time Frame
    3 months
    Title
    Atrial Flutter
    Description
    1. Flutter Acute Procedural Success 2. Freedom from Flutter Chronic Treatment Failure
    Time Frame
    3 months

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Documented paroxysmal atrial fibrillation ≥ 18 and ≤ 85 years of age Failure of one or more AF Drugs (AFDs). Referral for a pulmonary vein isolation catheter ablation procedure to treat atrial fibrillation Ability to understand the requirements of the study Willingness to adhere to study restrictions and comply with all post- procedural follow-up requirements Exclusion Criteria: Any reversible cause of AF (post-surgery, thyroid disorder, etc.) More than 4 cardioversions in the prior year. Patients with recent myocardial infarction (less than 2 months) or unstable angina. Patients with congestive heart failure (NYHA class III or IV). Patients who have experienced any cerebral ischemic event, including any TIA in the preceding 1 month. Women who are known to be pregnant or have had a positive β-HCG test 7 days prior to procedure. Patients with any other significant uncontrolled or unstable medical condition (including uncontrolled clinically significant coagulation disorders). Patients whose life expectancy is less than one year.
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Vivek Y Reddy, MD
    Organizational Affiliation
    Icahn School of Medicine at Mount Sinai
    Official's Role
    Principal Investigator

    12. IPD Sharing Statement

    Plan to Share IPD
    No
    Citations:
    PubMed Identifier
    16908781
    Citation
    Fuster V, Ryden LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, Halperin JL, Le Heuzey JY, Kay GN, Lowe JE, Olsson SB, Prystowsky EN, Tamargo JL, Wann S, Smith SC Jr, Jacobs AK, Adams CD, Anderson JL, Antman EM, Halperin JL, Hunt SA, Nishimura R, Ornato JP, Page RL, Riegel B, Priori SG, Blanc JJ, Budaj A, Camm AJ, Dean V, Deckers JW, Despres C, Dickstein K, Lekakis J, McGregor K, Metra M, Morais J, Osterspey A, Tamargo JL, Zamorano JL; American College of Cardiology/American Heart Association Task Force on Practice Guidelines; European Society of Cardiology Committee for Practice Guidelines; European Heart Rhythm Association; Heart Rhythm Society. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients With Atrial Fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation. 2006 Aug 15;114(7):e257-354. doi: 10.1161/CIRCULATIONAHA.106.177292. No abstract available. Erratum In: Circulation. 2007 Aug 7;116(6):e138.
    Results Reference
    background
    PubMed Identifier
    17556213
    Citation
    European Heart Rhythm Association (EHRA); European Cardiac Arrhythmia Scoiety (ECAS); American College of Cardiology (ACC); American Heart Association (AHA); Society of Thoracic Surgeons (STS); Calkins H, Brugada J, Packer DL, Cappato R, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, Haines DE, Haissaguerre M, Iesaka Y, Jackman W, Jais P, Kottkamp H, Kuck KH, Lindsay BD, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Natale A, Pappone C, Prystowsky E, Raviele A, Ruskin JN, Shemin RJ. HRS/EHRA/ECAS expert Consensus Statement on catheter and surgical ablation of atrial fibrillation: recommendations for personnel, policy, procedures and follow-up. A report of the Heart Rhythm Society (HRS) Task Force on catheter and surgical ablation of atrial fibrillation. Heart Rhythm. 2007 Jun;4(6):816-61. doi: 10.1016/j.hrthm.2007.04.005. Epub 2007 Apr 30. No abstract available. Erratum In: Heart Rhythm. 2009 Jan;6(1):148.
    Results Reference
    background
    PubMed Identifier
    18313591
    Citation
    Reddy VY, Neuzil P, d'Avila A, Laragy M, Malchano ZJ, Kralovec S, Kim SJ, Ruskin JN. Balloon catheter ablation to treat paroxysmal atrial fibrillation: what is the level of pulmonary venous isolation? Heart Rhythm. 2008 Mar;5(3):353-60. doi: 10.1016/j.hrthm.2007.11.006. Epub 2007 Nov 7.
    Results Reference
    background
    PubMed Identifier
    17569680
    Citation
    Van Belle Y, Janse P, Rivero-Ayerza MJ, Thornton AS, Jessurun ER, Theuns D, Jordaens L. Pulmonary vein isolation using an occluding cryoballoon for circumferential ablation: feasibility, complications, and short-term outcome. Eur Heart J. 2007 Sep;28(18):2231-7. doi: 10.1093/eurheartj/ehm227. Epub 2007 Jun 14.
    Results Reference
    background
    PubMed Identifier
    15673379
    Citation
    Tsao HM, Wu MH, Huang BH, Lee SH, Lee KT, Tai CT, Lin YK, Hsieh MH, Kuo JY, Lei MH, Chen SA. Morphologic remodeling of pulmonary veins and left atrium after catheter ablation of atrial fibrillation: insight from long-term follow-up of three-dimensional magnetic resonance imaging. J Cardiovasc Electrophysiol. 2005 Jan;16(1):7-12. doi: 10.1046/j.1540-8167.2005.04407.x.
    Results Reference
    background
    PubMed Identifier
    16171744
    Citation
    Lemola K, Desjardins B, Sneider M, Case I, Chugh A, Good E, Han J, Tamirisa K, Tsemo A, Reich S, Tschopp D, Igic P, Elmouchi D, Bogun F, Pelosi F Jr, Kazerooni E, Morady F, Oral H. Effect of left atrial circumferential ablation for atrial fibrillation on left atrial transport function. Heart Rhythm. 2005 Sep;2(9):923-8. doi: 10.1016/j.hrthm.2005.06.026.
    Results Reference
    background
    PubMed Identifier
    16836670
    Citation
    Verma A, Kilicaslan F, Adams JR, Hao S, Beheiry S, Minor S, Ozduran V, Claude Elayi S, Martin DO, Schweikert RA, Saliba W, Thomas JD, Garcia M, Klein A, Natale A. Extensive ablation during pulmonary vein antrum isolation has no adverse impact on left atrial function: an echocardiography and cine computed tomography analysis. J Cardiovasc Electrophysiol. 2006 Jul;17(7):741-6. doi: 10.1111/j.1540-8167.2006.00488.x.
    Results Reference
    background
    PubMed Identifier
    16260634
    Citation
    Reant P, Lafitte S, Jais P, Serri K, Weerasooriya R, Hocini M, Pillois X, Clementy J, Haissaguerre M, Roudaut R. Reverse remodeling of the left cardiac chambers after catheter ablation after 1 year in a series of patients with isolated atrial fibrillation. Circulation. 2005 Nov 8;112(19):2896-903. doi: 10.1161/CIRCULATIONAHA.104.523928. Epub 2005 Oct 31.
    Results Reference
    background
    PubMed Identifier
    16820627
    Citation
    Yamanaka K, Fujita M, Doi K, Tsuneyoshi H, Yamazato A, Ueno K, Zen E, Komeda M. Multislice computed tomography accurately quantifies left atrial size and function after the MAZE procedure. Circulation. 2006 Jul 4;114(1 Suppl):I5-9. doi: 10.1161/CIRCULATIONAHA.105.000968.
    Results Reference
    background

    Learn more about this trial

    Effect of Balloon Cryoablation on Left Atrial Function

    We'll reach out to this number within 24 hrs